Ad is loading...
ACUT
Price
$0.42
Change
-$0.00 (-0.00%)
Updated
Nov 14 closing price
TELIF
Price
$0.28
Change
-$0.03 (-9.68%)
Updated
Nov 15 closing price
Ad is loading...

ACUT vs TELIF

Header iconACUT vs TELIF Comparison
Open Charts ACUT vs TELIFBanner chart's image
Accustem Sciences
Price$0.42
Change-$0.00 (-0.00%)
Volume$3.03K
CapitalizationN/A
TELESCOPE INNOVATIONS
Price$0.28
Change-$0.03 (-9.68%)
Volume$110K
CapitalizationN/A
ACUT vs TELIF Comparison Chart
Loading...
View a ticker or compare two or three
VS
ACUT vs. TELIF commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACUT is a Hold and TELIF is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (ACUT: $0.42 vs. TELIF: $0.28)
Brand notoriety: ACUT and TELIF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACUT: 105% vs. TELIF: 1032%
Market capitalization -- ACUT: $4.76M vs. TELIF: $13.74M
ACUT [@Biotechnology] is valued at $4.76M. TELIF’s [@Biotechnology] market capitalization is $13.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACUT’s FA Score shows that 1 FA rating(s) are green whileTELIF’s FA Score has 0 green FA rating(s).

  • ACUT’s FA Score: 1 green, 4 red.
  • TELIF’s FA Score: 0 green, 5 red.
According to our system of comparison, ACUT is a better buy in the long-term than TELIF.

Price Growth

ACUT (@Biotechnology) experienced а +15.04% price change this week, while TELIF (@Biotechnology) price change was -8.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
TELIF($13.7M) has a higher market cap than ACUT($4.76M). TELIF YTD gains are higher at: 108.605 vs. ACUT (-32.891). TELIF has higher annual earnings (EBITDA): -436.22K vs. ACUT (-1.74M). TELIF has more cash in the bank: 374K vs. ACUT (9.37K). TELIF has higher revenues than ACUT: TELIF (3.9M) vs ACUT (0).
ACUTTELIFACUT / TELIF
Capitalization4.76M13.7M35%
EBITDA-1.74M-436.22K399%
Gain YTD-32.891108.605-30%
P/E RatioN/A85.38-
Revenue03.9M-
Total Cash9.37K374K3%
Total DebtN/A2.02M-
TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BDCX30.950.14
+0.47%
ETRACS Qrtly Py 1.5X Lvgd Wls Fg BDC ETN
DIAL17.76-0.02
-0.11%
Columbia Diversified Fixed Inc Allc ETF
GMOM29.32-0.08
-0.28%
Cambria Global Momentum ETF
ZSB13.65-0.08
-0.55%
USCF Sustainable Battery Metals Stgy Fd
FLIN37.99-0.34
-0.89%
Franklin FTSE India ETF

ACUT and

Correlation & Price change

A.I.dvisor tells us that ACUT and KMSTF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACUT and KMSTF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACUT
1D Price
Change %
ACUT100%
N/A
KMSTF - ACUT
28%
Poorly correlated
N/A
MOLN - ACUT
21%
Poorly correlated
+1.52%
BIOR - ACUT
20%
Poorly correlated
-10.92%
PHGE - ACUT
20%
Poorly correlated
-17.33%
TELIF - ACUT
11%
Poorly correlated
-9.16%
More

TELIF and

Correlation & Price change

A.I.dvisor tells us that TELIF and ATNM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TELIF and ATNM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TELIF
1D Price
Change %
TELIF100%
-9.16%
ATNM - TELIF
31%
Poorly correlated
-9.09%
RVXCF - TELIF
22%
Poorly correlated
+1.65%
ENTX - TELIF
20%
Poorly correlated
-2.81%
ACUT - TELIF
11%
Poorly correlated
N/A
REVB - TELIF
9%
Poorly correlated
-4.02%
More